. We wished to examine the impact of social and cultural as well as biomedical factors. such as co-morbidity and prognostic factors at diagnosis. on patients' self-report of the experience of beginning treatment.
The methodology of international cancer clinical trials is constantly being improved and adapted as clinical questions evolve. The most recent step in this evolution is the inclusion of patient-rated quality of life (QL) as an end point for treatment comparison.
Social and cultural factors are an integral part of any individual's estimation or judgement of QL. The principles of QL assessment. however. have been established mostly within regional or national settings. Evaluating these social and cultural factors has only recently received attention. particularly in cancer clinical trials involving participants from multiple cultures (Hurny et al. 1992 ). The influence of such factors on cancer treatment comparisons based on QL is uncertain. and methods to adjust for them have rarely been discussed (Bernhard et al. 1996 : Cella et al. 1996 . We wished to examine the impact of social and cultural as well as biomedical factors. such as co-morbidity and prognostic factors at diagnosis. on patients' self-report of the experience of beginning treatment.
We examined three specific hypotheses. Based on prior experience in the Group. we expected substantial heterogeneity of baseline QL in the various languagelcultural groups: we expected worse baseline QL with worse prognostic factors. both because perception of these factors may colour the information given to the patient and because worse QL had previously been reported among patients with receptor-negative tumours (Razavi et al. 1990 ). and we expected worse baseline QL scores in patients living alone or only with children. based on the social support paradigm.
We therefore analysed the relationship between biomedical. sociodemographic and cultural factors and five indicators of components of QL recorded at baseline assessment in two intemational adjuvant breast cancer trials (Hurny et al. 1 996a) . This investigation identified covariates which need to be considered when interpreting baseline QL and evaluating the influence of treatment factors on QL in international breast cancer clinical trials.
METHODS
The trials Between July 1986 and April 1993. two International Breast Cancer Study Group (IBCSG) trials examined similar questions of timing and duration of adjuvant cytotoxic therapy for patients with node-positive operable breast cancer. In trial VI. we randomized 1475 eligible premenopausal and perimenopausal patients in a 2 x 2 factorial design to receive three or six initial cycles of chemotherapy using oral cyclophosphamide. intravenous methotrexate and 5-fluorouracil (CMF). with or without three later single cycles of reintroduction CMF administered at 3-month intervals. At the same time. 1212 eligible post-menopausal patients were randomized in IBCSG trial VII. All postmenopausal patients received 20 mg of tamoxifen daily for 5 years. Tamoxifen alone was compared with chemo-endocrine therapy. adding three initial cycles of CMF. three delayed CMF cycles administered at months 9. 12 and 15 or both early and delayed CMF. Eligibility criteria have been reported (International Breast Cancer Study Group. 1996 . 1997 
0L assessment
The QL form included five indicators of components of healthrelated QL especially relevant in adjuvant breast cancer patients (Hurny et al. 1992) . Physical wellbeing. mood. appetite (Priestman and Baum. 1976: Coates et al. 1987) and perceived adjustment to chronic illness (PACIS) (Hurny et al. 1993) were assessed with single-item linear analogue self-assessment (LASA) scales. previously validated in several cancer populations (Coates et al. 1983 : Coates et al. 1990 : Butow et al. 1991 ). An additional assessment of emotional wellbeing used the 'Befindlichkeitsskala' (Bf-S). a psychometrically characterized 28-item adjective checklist (Zerssen. 1976 : Zerssen. 1986 ). The relationship between the mood LASA and the Bf-S has been reported elsewhere (Hurny et al. 1996b) . QL forms were translated into the seven required main languages by professional translators, pilot tested by physicians and patients in the relevant centres and adjusted in the light of their feedback to ensure not only linguistic. but also conceptual.
equivalence. The LASA translations were further checked by an independent forward-backward' translation procedure.
In accordance with prior validated use of these instruments. patients were asked to fill in the scales referring to different time frames. The LASA scales for physical wellbeing. mood and appetite were related to the 'entire period since your last full clinical assessment'. while the Bf-S was related to the 'present state or the way you feel now'. The time frame of the PACIS was not specified.
The protocols required that adjuvant therapy began within 6 weeks of surgery and that patients completed the baseline QL questionnaire on. or as close as possible to. day I of adjuvant therapy. before the administration of treatment. Patients were asked to mark a cross on a 1 00-mm line to rate mood overall for the entire period since their last full clinical assessment Higher scores reflect better mood. "Transformed mean as described in Statistical methods.
average. above). Culture was defined by nine broad language/ country groupings (English/Australia or New Zealand: English/ South Africa: French/Switzerland: German/Switzerland or Germany: Italian/Switzerland: Italian/Italy: Slovenian/Slovenia: Spanish/Spain: Swedish/Sweden). recognizing that in these data language is inextricably associated with culture. German-speaking patients from Switzerland and Germany were combined because there were only 14 from Germany. (Hurny et al, 1994) . In this analysis. Table 1 shows the culture groups, along with the number of institutions and the number of patients included in each.
Cultural factors Overall. cultural factors had the strongest impact on baseline QL and affected all five measures in both trials (P < 0.0001 for all. except for appetite and physical wellbeing in trial VII, which were P = 0.05 and 0.003 respectively). For example, Table 2 shows the means of the mood scale according to culture. The pattern of mood scores across culture groups was similar within the two trials. Two of the languages were used in more than one country. allowing for comparisons between countries within the same language. QL scores for English-speaking patients from Australia/New Zealand were similar to those for English-speaking patients from South Africa (Table 2 ). In contrast. Italian-speaking patients from northern Italy reported substantially lower mood scores than those from the adjoining southern part of Switzerland (P = 0.01 in trial VI. P = 0.002 in trial VII; Table 2 ). All other QL scales showed differences in the same direction, although not all of the differences were statistically significant.
Overall. the variance explained by these cultural factors was modest. It ranged from 3% (Bf-S. physical wellbeing) to 8% (mood) in trial VI (premenopausal and perimenopausal patients). and from 2% (physical wellbeing. appetite) to 6% (mood. PACIS) in trial VII (post-menopausal patients).
Biomedical factors
After controlling for cultural effects, biomedical factors also had an impact on the QL measures, as summarized in Table 3 . The mood and adjustment scales were most responsive to these factors. The effects of tumour and non-tumour related biomedical factors were different in the two trials.
Age had a significant impact in post-menopausal patients only. Older patients (60+ years) reported better emotional wellbeing (P = 0.002) and mood (P = 0.002), and less effort to cope (P = 0.0009) compared with younger post-menopausal patients (Table 4) . Although older patients were more likely to have total mastectomies (71% for patients under 55 years to 79% for patients 65 years and alder), the age effect was independent of type of primary surgery.
Presence of concomitant chronic disease was associated with a tendency to worse physical wellbeing in post-menopausal patients (no co-morbidity: mean = 79.7: with co-morbidity: mean = 76.2. P = 0.02). As expected, co-morbidity was more prevalent in postmenopausal (33%) than premenopausal (13%) patients. Type of surgery had an impact on mood in post-menopausal patients only. Those treated with mastectomy reported better mood scores than those treated with conservation plus radiotherapy (76.1 vs. 70.8. P = 0.006). An effect of systemic adjuvant treatment assignment was observed in trial VII. Patients assigned to receive tamoxifen only reported better appetite (mean = 88.3) than those who were to undergo additional early (mean = 82.7), late (mean = 83.6). or early and late chemotherapy (mean = 84.5, P = 0.007).
In general, patients whose tumours had characteristics associated with poorer prognoses reported worse QL. Premenopausal British Journal of Cancer (1998) 
Country differences within language
We also investigated whether or not there was a differential impact of biomedical and sociodemographic factors on global QL indicators between different countries within the same language group. Mood and adjustment were analysed separately in the two English-speaking groups (South Africa and Australia/New Zealand) within each trial and in the two Italian-speaking groups (Italy and Switzerland) within each trial. Although some differences were observed, there were no consistent patterns, suggesting that these factors have a similar impact on patient self-estimation within language groups. They do not explain the overall difference in mood between Italian-speaking patients from Italy and Italianspeaking patients from Switzerland.
DISCUSSION
Individual patients' baseline QL scores vary considerably within cancer clinical trials. They are highly predictive of the level of subsequent QL assessments and therefore relevant for investigating treatment-related changes. We analysed how biomedical. sociodemographic and cultural factors affected baseline scores of two large-scale adjuvant breast cancer trials (Hurny et al. 1996a) and now report these associations in more detail. This information will be useful for investigators in determining which additional variables need to be assessed in breast cancer clinical trials.
Cultural factor
This investigation has confirmed and substantially extended our previous report (Hurny et al. 1992 ) that cultural and language factors affect patient-rated QL and, therefore. need to be considered in cross-cultural trials. although their contribution to the total variance in QL scores is modest. Although it remains possible that these findings are due to imperfect translation, we believe this is unlikely given the thorough multistep translation procedure which was used.
Before concluding that there are 'true' cultural differences. we should also consider institutional factors and the possibility of selective recruitment of patients with different characteristics, or differences in patient care in the various cultures. This may account for the differences seen between the Italian-speaking Swiss and the patients from northern Italy. The participating hospitals in Italy are larger, the waiting rooms are more crowded. and patients may feel more anonymous at the beginning of treatment than in the Swiss outpatient clinics. Also, the generally higher QL scores in Switzerland compared with Slovenia may reflect true overall socioeconomic differences between the two countries. It is also possible that systematic differences among cultures in the degree and method of doctor-patient communication about the details of the tumour and its treatment may underlie part of the observed cultural differences in QL.
On the other hand, in the case that patients from different cultures report similar QL scores (e.g. English-speaking patients from Australia/New Zealand and South Africa), this similarity may hide true cultural differences in perceptions, attitudes and habits. Although these differences are not relevant for overall treatment comparisons, in subgroup analyses an isolated interpretation of either symptoms or any aspect of QL without regard to the institutional, social and cultural context could be misleading (Huimy et al, 1993) .
In summary, the overall differences among the investigated cultures probably reflect cultural differences in patients' response to disease and treatment sequelae, such as a tendency to stoic selfcontrol or exasperated emotional expression in particular cultures. This is especially relevant for highly 'subjective' concepts such as 'coping' (PACIS). but was also seen in appetite, a relatively concrete sensation.
Biomedical factors
Age had an effect on QL in post-menopausal patients only. Postmenopausal patients under 60 reported worse emotional and adjustment scores than older patients. To our knowledge. the role of age in the adjustment to diagnosis and treatment has not been reported separately within menopausal status groups (Vinokur et al, 1990; Ganz et al, 1993 : Mor et al. 1994 , except in one study in which increased anxiety was observed in patients in their fifties treated by mastectomy (Maraste et al, 1992) .
Co-morbidity was much more frequent in post-menopausal patients. It had a weak negative impact on physical wellbeing in both trials, but was significantly associated with physical wellbeing only in post-menopausal patients.
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Extent of surgery was a significant factor associated with mood in post-menopausal patients, with patients who had had total mastectomies reporting better mood scores. At the start of adjuvant therapy. emotional distress is characterized by anxiety rather than depression (Maraste et al. 1992) . A total mastectomy could have relieved anxiety regarding disease progression in these patients (Fallowfield et al. 1990 (Kiebert et al. 1991; Ganz et al. 1992 : Pozo et al. 1992 . The relationship between ER status and mood is in agreement with the finding reported by Razavi (1990 : Hurny, 1993 .
The effect of treatment assignment on appetite in postmenopausal patients is probably an anticipatory effect. Patients were informed about the allocated treatment before completing the QL form. patients assigned to receive tamoxifen only reported better baseline appetite scores than those assigned to receive late chemotherapy only. As reported in the analysis of the impact of treatment on subsequent QL in these trials (Hurny et al. 1996a 
Sociodemographic factors
Sociodemographic factors showed a relatively weak association with baseline QL. which was seen in post-menopausal patients only. Overall, we found no major effect of these factors on QL.
However. these factors have been shown to predict survival in breast (Karjalainen and Pukkala. 1990: Schrijvers et al. 1995) and other cancers. and we suggest that in large-scale international trials at least one indicator of socioeconomic status (e.g. educational level) be recorded.
Furher investigations
More information is needed about the perception and understanding of cancer and its treatment in various cultures. The question of how interactions among cultural. social and biomedical factors affect QL in cancer clinical trial settings warrants further study. not just for baseline scores, but also for QL during treatment and follow-up. In addition. the generalizability of the effect of biomedical interventions on QL should be investigated within international clinical trials.
Only a modest part of the variance in QL scores was explained by the factors investigated. In contrast, individual psychosocial factors, such as stressful life events before diagnosis (Maunsell et al. 1992) . history of depression (Maunsell et al. 1992) . attitudes (Carver et al. 1994 ) and social support (Irvine et al. 1991 
